Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Psoriatic onychodystrophy is observed in about 80% of patients with psoriasis. Psoriasis can affect two nail structures ― the matrix and the nail bed.

Involvement of the nail matrix in the pathological process can lead to the formation of leukonychia, thimble symptom, red spots in the area of the hole and destruction of the nail plate. On the other hand, the lesion of the nail bed is characterized by the formation of onycholysis, subcutaneous hyperkeratosis and subcutaneous hemorrhages.

Nail lesions in psoriasis are accompanied by functional disorders and aesthetic defects, and also indicate a severe course of psoriasis.

Treatment of psoriatic onychodystrophy includes topical medications, systemic therapy in cases accompanied by extensive skin lesions.

This article is an overview of the main clinical features, diagnostic issues and evaluation methods, as well as treatment options for nail psoriasis.

Full Text

Restricted Access

About the authors

Alexey Viktorovich Taganov

Peoples' Friendship University of Russia

Author for correspondence.
Email: mais87177@yandex.ru
ORCID iD: 0000-0001-5056-374X
SPIN-code: 1191-8991

MD, Dr. Sci. (Med.), Professor

Russian Federation, 6 Miklukho-Maklaya street, 117198 Moscow

Anton V. Molochkov

Peoples' Friendship University of Russia

Email: antmd@yandex.ru
ORCID iD: 0000-0002-6456-998X
SPIN-code: 8853-5050

MD, Dr. Sci. (Med.), Professor

Russian Federation, 6 Miklukho-Maklaya street, 117198 Moscow

Natalya G. Kulikova

Peoples' Friendship University of Russia

Email: kulikovang777@mail.ru
ORCID iD: 0000-0002-6895-0681
SPIN-code: 1827-7880

MD, Dr. Sci. (Med.), Professor

Russian Federation, 6 Miklukho-Maklaya street, 117198 Moscow

Alawi Mohammad Ali Mohammad

Peoples' Friendship University of Russia

Email: Alawi4jan1980@gmail.com
ORCID iD: 0000-0002-5632-5088
Russian Federation, 6 Miklukho-Maklaya street, 117198 Moscow

Maria K. Monaenkova

Moscow Regional Research and Clinical Institute

Email: mar.monaenkova@gmail.com
ORCID iD: 0000-0001-8479-1978
SPIN-code: 9662-8661

Junior Researcher

Russian Federation, Moscow

Denis V. Zaslavsky

Saint Petersburg State Pediatric Medical University

Email: venerology@gmail.com
ORCID iD: 0000-0001-5936-6232
SPIN-code: 5832-9510

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Daria V. Kozlova

Saint Petersburg State Pediatric Medical University

Email: dashauchenaya@yandex.ru
ORCID iD: 0000-0002-6942-2880
SPIN-code: 3783-8565
Russian Federation, Saint Petersburg

References

  1. liang Y, Sarkar K, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;(49):1–8. doi: 10.1016/j.coi.2017.07.007
  2. Potekaev NN, Zhukova OV, Artemieva SI. Successful using of netakimab in treatment of psoriasis, accompanying by psoriatic onychodistrophy. Med Advice. 2020;(12):64–70. (In Russ). doi: 10.21518/2079-701X-2020-12-64-70
  3. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015
  4. Kovaleva YS, Vedler AA, Subbotin EA, Gribova GV. Psoriatic onychodistrophy asa marker of psoriasis severity and comorbidity. Vestnik SurGU. Meditsina. 2020;(4):51–57. (In Russ). doi: 10.34822/2304-9448-2020-4-51-57
  5. Baran R. The burden of nail psoriasis: An introduction. Dermatology. 2010;221(Suppl 1):1–5. doi: 10.1159/000316169
  6. Tan ES, Chong WS, Tey HL. Nail psoriasis: A review. Am J Clin Dermatol. 2012;13(6):375–388. doi: 10.2165/11597000-000000000-00000
  7. Platonova AV, Zhukov AS, Khairutdinov VR, Samtsov AV. Psoriatic onychodistrophy: Clinical features (part 1). Bulletin Dermatol Venereol. 2018;94(6):7–14. (In Russ). doi: 10.25208/0042-4609-2018-94-6-7-14
  8. Platonova AV. Psoriaticheskaya onichodistrofiya: epidemiolgiya, kliniko-laboratornaya diagnostika, lechenie [dissertation abstract]. Saint Petersburg; 2022. 32 р. (In Russ).
  9. Sukolina OS. Assessment of the severity of nail damage in psoriasis using NAPSI. Russ J Skin Venereal Dis. 2007;(5):83–85. (In Russ).
  10. Haneke E. Nail psoriasis: Clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;(7):51–63. doi: 10.2147/PTT.S126281
  11. Brazzelli V, Carugno A, Alborghetti A, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol. 2012;26(11):1354–1359. doi: 10.1111/j.1468-3083.2011.04289.x
  12. Armesto S, Esteve A, Coto-Segura P, et al. [Nail psoriasis in individuals with psoriasis vulgaris: A study of 661 patients. (In Spanish)]. Actas Dermosifiliogr. 2011;102(5):365–372. doi: 10.1016/j.ad.2011.02.007
  13. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: Epidemiology and burden of disease. Br J Dermatol. 2010;(163):580–585. doi: 10.1111/j.1365-2133.2010.09831.x
  14. Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body loca-tions: Data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. doi: 10.1186/s12895-020-00099-7
  15. Prignano F, Rogai V, Cavallucci E, et al. Epidemiology of psoriasis and psoriatic arthritis in Italya systematic review. Curr Rheumatol Rep. 2018;20(7):43. doi: 10.1007/s11926-018-0753-1
  16. Blome C, Costanzo A, Dauden E, et al. Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res. 2016;25(5):1179–1188. doi: 10.1007/s11136-015-1136-y
  17. Van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatol. 2014;229(2):76–82. doi: 10.1159/000360696
  18. Blome C, Augustin M, Klein TM. Nail psoriasis and quality-of-life measurement in clinical trials: Call for the use of nail-specific instruments. Am J Clin Dermatol. 2021;22(6):747–755. doi: 10.1007/s40257-021-00622-7
  19. Schäfer I, Rustenbach SJ, Radtke M, et al. [Epidemiology of psoriasis in Germany: Analysis of secondary health insurance data. (In German)]. Gesund-Heitswesen. 2011;73(5):308–313. doi: 10.1055/s-0030-1252022
  20. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: A prospective clinical study. J Cutan Med Surg. 2003;7(4):317–21. doi: 10.1007/s10227-002-0143-0
  21. De Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1,728 patients. Dermatol. 1996;193(4):300–303. doi: 10.1159/000246274
  22. Gregoriou S, Kalogeromitros D, Kosionis N, et al. Treatment options for nail psoriasis. Expert Rev Dermatol. 2008;3(3):339–344. doi: 10.1586/17469872.3.3.339
  23. Mrovits U, Makleidt O, Eike K. A modern view on the treatment of psoriasis with nail plate damage. Polyclinic. 2013;(2):100–105. (In Russ).
  24. Schons KR, Beber AA, Beck Mde O, Monticielo OA. Nail involvement in adult patients with plaque-type psoriasis: Prevalence and clinical features. An Bras Dermatol. 2015;90(3):314–319. doi: 10.1590/abd1806-4841.20153736
  25. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail Psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28(12):1690–1695. doi: 10.1111/jdv.12368
  26. Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi: 10.1016/j.jaad.2005.07.073
  27. Sergeev YV, Sergeev AY. Onychomycoses: Mycological infections of the nails. Moscow: GEOTAR-Meditsyna; 1998. 38 р. (In Russ).
  28. Singh G. Nails in systemic disease. Indian J Dermatol Venereol Leprol. 2011;77(6):646–651. doi: 10.4103/0378-6323.86472
  29. Gregoriou S, Argyriou G, Larios G, Rigopoulos D. Nail disorders and systemic disease: What the nails tell us. J Fam Pract. 2008;(57):509–514.
  30. Hanno R, Mathes BM, Krull EA. Longitudinal nail biopsy in evaluation of acquired nail dystrophies. J Am Acad Dermatol. 1986;14(5 Pt 1):803–809. doi: 10.1016/s0190-9622(86)70097-2
  31. Micali G, Lacarrubba F, Massimino D, Schwartz RA. Dermatoscopy: Alternative uses in daily clinical practice. J Am Acad Dermatol. 2011;64(6):1135–1146. doi: 10.1016/j.jaad.2010.03.010
  32. Yadav TA, Khopkar US. Dermoscopy to detect signs of subclinical nail involvement in chronic plaque psoriasis: A study of 68 patients. Indian J Dermatol. 2015;60(3):272–275. doi: 10.4103/0019-5154.156377
  33. Grover C, Jakhar D. Onychoscopy: A practical guide. Indian J Dermatol Venereol Leprol. 2017;83(5):536–549. doi: 10.4103/ijdvl.IJDVL_242_16
  34. Staberg B, Gammeltoft M, Onsberg P. Onychomycosis in patients with psoriasis. Acta Derm Venereol. 1983;(63):436–438.
  35. Natarajan V, Nath AK, Thappa DM, et al. Coexistence of onychomycosis in psoriatic nails: A descriptive study. Indian J Dermatol Venereol Leprol. 2010;76(6):723. doi: 10.4103/0378-6323.72468
  36. Szepietowski JC, Salomon J. Do fungi play a role in psoriatic nails? Mycoses. 2007;50(6):437–442. doi: 10.1111/j.1439-0507.2007.01405.x
  37. Schwartz RA. Erythema dyschromicum perstans: The continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol. 2004;43(3):230–232. doi: 10.1111/j.1365-4632.2004.02001.x
  38. Tschen JA, Tschen EA, McGavran MH. Erythema dyschromicum perstans. J Am Acad Dermatol. 1980;2(4):295–302. doi: 10.1016/s0190-9622(80)80041-7
  39. Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–212. doi: 10.1067/s0190-9622(03)00910-1
  40. Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: Validation of an instrument to assess psoriatic nail involve-ment in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–129.
  41. Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol. 2005;53(4):745–746. doi: 10.1016/j.jaad.2004.11.044
  42. Rusk AM, Fleischer AB. In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. J Dermatolog Treat. 2021;32(8):894–897. doi: 10.1080/09546634.2020.1720578
  43. De Jong EM, Menke HE, van Praag MC, van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatol. 1999;199(4):313–318. doi: 10.1159/000018281
  44. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: Out-come of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834–839. doi: 10.1093/rheumatology/33.9.834
  45. Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–27. doi: 10.1111/j.1468-3083.2009.03344.x
  46. Fredriksson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica. 1978;(157):238–244. doi: 10.1159/000250839
  47. Augustin M, Blome C, Costanzo A, et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): Development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;(170):591–598. doi: 10.1111/bjd.12664
  48. Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436. doi: 10.1111/bjd.19262
  49. Yin S, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): Development and testing of a one-factor model. Popul Health Metr. 2016;(14):22. doi: 10.1186/s12963-016-0091-3
  50. Prinsen CA, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–1157. doi: 10.1007/s11136-018-1798-3
  51. Rigopoulos D, Rompoti N, Gregoriou S. Management of nail psoriasis. Dermatol Clin. 2021;39(2):211–220. doi: 10.1016/j.det.2020.12.014
  52. Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: An updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99(6):516–523. doi: 10.2340/00015555-3098
  53. Ricardo JW, Lipner SR. Nail psoriasis in older adults: Epidemiology, diagnosis, and topical therapy. Dermatol Clin. 2021;39(2):183–193. doi: 10.1016/j.det.2020.12.011
  54. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: A randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol. 2012;66(5):807–812. doi: 10.1016/j.jaad.2011.12.015
  55. Nakamura RC, Abreu LD, Duque-Estrada B, et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: Prospective, controlled and randomized pilot study. An Bras Dermatol. 2012;87(2):203–211. doi: 10.1590/s0365-05962012000200003
  56. Fischer-Levancini C, Sánchez-Regaña M, Llambí F, et al. Nail psoriasis: Treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr. 2012;103(8):725–728. doi: 10.1016/j.ad.2012.04.008
  57. De Simone C, Maiorino A. Tassone F, et al. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol. 2012;27(8):1003–1006. doi: 10.1111/j.1468-3083.2012.04642.x
  58. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279–280. doi: 10.2340/00015555-0401
  59. Sánchez Regaña M, Márquez Balbás G, Millet PU. Nail psoriasis: A combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol. 2008;22(8):963–969. doi: 10.1111/j.1468-3083.2008.02679.x
  60. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: A double-blind study. Acta Derm Venereol. 2007;87(2):167–168. doi: 10.2340/00015555-0195
  61. Regaña MS, Ezquerra GM, Millet PU, Mateos FL. Treatment of nail psoriasis with 8% clobetasol nail lacquer: Positive experience in 10 patients. J Eur Acad Dermatol Venereol. 2005;19(5):573–577. doi: 10.1111/j.1468-3083.2005.01253.x
  62. Cannavò SP, Guarneri F. Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153–153. doi: 10.1159/000068469
  63. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: An open, prospective study. Br J Dermatol. 2003;149(1):207–209. doi: 10.1046/j.1365-2133.2003.05392.x
  64. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140. doi: 10.1080/00015550252948220
  65. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: A dou-ble-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–358.
  66. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treatment. 1999;10(3):201–204.
  67. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–659. doi: 10.1046/j.1365-2133.1998.02462.x
  68. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol. 1998;25(4):231–233. doi: 10.1111/j.1346-8138.1998.tb02386.x
  69. Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110(5):735–736.
  70. Hadeler E, Mosca M, Hong J, et al. Nail psoriasis: A review of effective therapies and recommendations for managementet. Dermatol Ther (Heidelb). 2021;11(3):799–831. doi: 10.1007/s13555-021-00523-x
  71. Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients. Br J Dermatol. 2001;144(5):1000–1005. doi: 10.1046/j.1365-2133.2001.04189.x
  72. De Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25(5):357–362. doi: 10.1046/j.1365-2230.2000.00663.x
  73. Bedi TR. Intradermal triamcinolone treatment of psoriatic onychodystrophy. Dermatologica. 1977;155(1):24–27. doi: 10.1159/000250951
  74. Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: A study of 24 cases. Dermatol Online J. 2005;11(3):5.
  75. Fritz K. [Successful local treatment of nail psoriasis with 5-fluorouracil. (In German)]. Z Hautkr. 1989;64(12):1083–1088.
  76. McDermott L, Madan R, Rupani R, Siegel D. A review of indigo naturalis as an alternative treatment for nail psoriasis. J Drugs Dermatol. 2016;15(3):319–323.
  77. Yew YW, Phuan CZ, Zhao X, et al. Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment. Ann Acad Med Singap. 2022;51(1):16–23. doi: 10.47102/annals-acadmedsg.2021380
  78. Reich K, Nestle FO, Papp K, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6
  79. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. doi: 10.1111/bjd.17351
  80. Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85(1):135–143. doi: 10.1016/j.jaad.2021.01.024
  81. Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat. 2022;33(3):1652–1660. doi: 10.1080/09546634.2021.1892024
  82. Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17, -12/23, -23 and small molecules targeting jak and pde4 in the treatment of nail psoriasis: A network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318. doi: 10.2340/00015555-3640
  83. Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol. 2005;52(6):1101–1102. doi: 10.1016/j.jaad.2005.01.101
  84. Körver JE, Langewouters AM, van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol. 2006;20(10):1252–1255. doi: 10.1111/j.1468-3083.2006.01783.x
  85. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol. 1980;116(9):1023–1024.
  86. Alawi MA, Molochkov AV, Kulikova NG. Physiotherapeutic complex for the treatment of patients with psoriatic onychodystrophy. Acta Biomed [Internet]. 2023;94(2):e2023137.
  87. Baranova U.A. Efficiency of treatment of psoriatic onychodystrophy by method of local photochemotherapy exposure. Vestnik SurGU. Meditsina. 2019;(3):51–56. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies